Humanistic and economic burden of cardiovascular disease related comorbidities and hypoglycaemia among patients with type 2 diabetes in Japan.

Cardiovascular disease Health related quality of life Healthcare resource utilization Hypoglycaemia Type 2 diabetes Work productivity and activity impairment

Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 26 09 2018
revised: 21 12 2018
accepted: 15 01 2019
pubmed: 28 1 2019
medline: 7 5 2019
entrez: 28 1 2019
Statut: ppublish

Résumé

This study aims to examine the humanistic and economic burden of cardiovascular disease (CVD)-related comorbidities and hypoglycaemia among respondents with type 2 diabetes (T2D) in Japan. This study used the Japan National Health and Wellness Survey 2016 database. Respondents who self-reported a physician-diagnosed T2D were included. Respondents with or without the condition of interest (CVD-related comorbidities or hypoglycaemia) were compared via generalized linear models in terms of the outcome variables: (1) health-related quality of life (HRQoL), (2) work productivity and activity impairment, (3) healthcare resource utilization and (4) economic costs. A total of 1478 survey respondents reported a diagnosis of T2D (mean age 63.6 ± 10.6 years, mean HbA1c 6.91 ± 1.1%). Of whom, 804 subjects (54.4%) had at least one CVD related comorbidities, and 369 subjects (29.3%) reported experiences of hypoglycaemia episodes. Patients with CVD-related comorbidities or hypoglycaemia episodes had worse HRQoL, more work and activity impairment, increased health care visits, and higher costs. CVD related comorbidities and hypoglycaemia remains a significant humanistic and economic burden in patients with T2D. The findings suggested that appropriate T2D management with proper medication choice are important to control CVD related comorbidities and hypoglycaemia among T2D patients to alleviate the burden.

Identifiants

pubmed: 30685348
pii: S0168-8227(18)31334-2
doi: 10.1016/j.diabres.2019.01.019
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115-125

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Yasuo Terauchi (Y)

Yokohama City University School of Medicine, Yokohama, Japan. Electronic address: terauchi@yokohama-cu.ac.jp.

Asuka Ozaki (A)

Medical Affairs, Sanofi K.K., Japan.

Xiahong Zhao (X)

Kantar Health, Singapore.

Cheryl Teoh (C)

Kantar Health, Singapore.

Dena Jaffe (D)

Kantar Health, Tel Aviv, Israel.

Yuki Tajima (Y)

Medical Affairs, Sanofi K.K., Japan.

Yujin Shuto (Y)

Medical Affairs, Sanofi K.K., Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH